01:23 , Mar 31, 2018 |  BioCentury  |  Strategy

Refashioning Takeda

Takeda Pharmaceutical Co. Ltd.’s potential acquisition of Shire plc appears to be timed to take advantage of the chance to acquire products and a global footprint on the cheap. The combination would create a global...
19:58 , Aug 4, 2017 |  BC Week In Review  |  Company News

Shire evaluating neurology pipeline

In its 2Q17 earnings report, Shire plc (LSE:SHP; NASDAQ:SHPG) said it will evaluate options for its neurology franchise, with the potential of spinning out the company’s core ADHD business into an independent public company. The...
23:20 , Aug 3, 2017 |  BC Extra  |  Company News

Shire evaluating neurology pipeline

In its 2Q17 earnings report, Shire plc (LSE:SHP; NASDAQ:SHPG) said it will evaluate options for its neurology franchise, with the potential of spinning out the company’s core ADHD business into an independent public company. The...
21:34 , Aug 3, 2017 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: July 2017

New Therapeutic Targets and Biomarkers: July 2017...
19:21 , Jul 13, 2017 |  BC Innovations  |  Translation in Brief

Mind over matter

In the latest link between the GI tract and the CNS, a team from the Max Delbrück Center for Molecular Medicine has identified the synaptic organizers CADM1 and CADM2 as targets in the gut-brain axis...
18:05 , Jul 10, 2017 |  BC Innovations  |  Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Obesity Human sample and mouse studies suggest inhibiting CADM1 in the brain could help treat obesity. In brain tissue samples from non-obese surgery patients and postmortem subjects, levels of CADM1 in the hypothalamus were...
00:56 , Mar 29, 2017 |  BC Week In Review  |  Clinical News

CM-24: Ph I terminated

Merck terminated an open-label, dose-escalation, U.S. and Israeli Phase I trial evaluating CM-24 in combination with Keytruda pembrolizumab in 27 patients. The company said CM-24 showed no signs of efficacy in the trial and that...
19:44 , Mar 23, 2017 |  BC Extra  |  Clinical News

Merck ends development of cCAM compound

Merck & Co. Inc. (NYSE:MRK) terminated development of oncology candidate CM-24 , spokesperson Pamela Eisele told BioCentury. Eisele said the mAb showed no signs of efficacy in a dose-ranging Phase I study in combination with...
23:06 , Nov 3, 2016 |  BC Innovations  |  Targets & Mechanisms

Going against the gut

While patients might have a long wait for an HIV vaccine, several groups are working on the next best thing: strategies that boost patient immune systems to control the infection without the need for daily...
07:00 , Aug 4, 2016 |  BC Innovations  |  Product R&D

Antibiotic wisdom

While one of the biggest problems in infectious diseases is the overuse of antibiotics, few point-of-care tools are available to help physicians decide when and what to prescribe. Focusing on host genes rather than microbial...